B-cell type acute leukaemia
RecruitingStudy on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
- Disease:B-cell type acute leukaemia
- Substances:TocilizumabHuman Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
Italy- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Tocilizumab
- Sponsor:AstraZeneca AB










